FY2025 · period end Jun '25 · from the 10-K filed Aug 8, 2025
| Metric | FY25Jun '25 | FY24Jun '24 | FY23Jun '23 | FY22Jun '22 | FY21Jun '21 |
|---|---|---|---|---|---|
| Revenue | $7.10B |
Showing the most recent 5 annual periods. Get 15 years of history on the Pro plan, or unlimited history back to 1993 plus the smart-money dataset and webhooks on Institutional.
| Form | Accession ID | Report Date | Filing Date | Accepted At | Source |
|---|---|---|---|---|---|
| 8-K | 0001206774-26-000333 | Jun 14, 2026 | Jun 17, 2026 | Jun 17, 2026 20:15 UTC | EDGAR |
| 8-K | 0001206774-26-000296 | May 26, 2026 | May 28, 2026 | May 28, 2026 20:05 UTC | EDGAR |
| 8-K | 0001193125-26-216807 | May 6, 2026 | May 11, 2026 | May 11, 2026 20:15 UTC | EDGAR |
| 8-K | 0000021076-26-000016 | Apr 30, 2026 | Apr 30, 2026 | Apr 30, 2026 20:12 UTC | EDGAR |
| 10-Q | 0000021076-26-000019 | Mar 31, 2026 | Apr 30, 2026 | Apr 30, 2026 20:48 UTC | EDGAR |
| 8-K | 0001206774-26-000173 | Apr 1, 2026 | Apr 1, 2026 | Apr 1, 2026 12:01 UTC | EDGAR |
| 8-K | 0001206774-26-000133 | Mar 6, 2026 | Mar 10, 2026 | Mar 10, 2026 20:15 UTC | EDGAR |
| 8-K | 0000021076-26-000008 | Feb 3, 2026 | Feb 3, 2026 | Feb 3, 2026 21:11 UTC | EDGAR |
Direct links to SEC EDGAR. CLX has additional filings available on the SEC site.
Figures a later SEC filing revised from what was first reported. Each diff compares the same XBRL tag across two filings — both linked, so you can check it yourself.
Income (Loss) from Continuing Operations before Income Taxes, Foreign·FY 2014
Major restatementwas$105M
Revised up in a 10-K.
Income (Loss) from Continuing Operations before Income Taxes, Domestic·FY 2009
Major restatementwas$669M
Revised down in a 10-K.
Income (Loss) from Continuing Operations before Income Taxes, Domestic·FY 2010
Major restatementwas$773M
Revised down in a 10-K.
Income (Loss) from Continuing Operations before Income Taxes, Foreign·FY 2010
Notable restatementwas$152M
Revised down in a 10-K.
Gross Profit·FY 2010
Notable restatementwas$2.5B
Revised down in a 10-K.
Gross Profit·FY 2009
Notable restatementwas$2.3B
Revised down in a 10-K.
CLX is not the only one.
See every restatement we've found across the market — or get an alert the next time CLX revises a number.
Restatements are detected by comparing every vintage of a fact across all of CLOROX CO /DE/'s filings back to 1993. A revision is not by itself a sign of wrongdoing — companies re-file for many legitimate reasons. This list is not exhaustive: it shows CLX's most significant revisions, and a figure absent from it has not been certified as unrevised.
Who is buying and selling CLOROX CO /DE/ — insider transactions from Forms 3/4/5/144 and institutional ownership from 13F, 13D, and 13G filings, point-in-time stamped like every other fact in the library. Traders read it as a positioning signal; risk desks read it as concentration.
No published research on CLX yet.
Reports appear here as analysts publish research on this company — built with Valuein's agentic workflows, every figure pinned to its SEC filing. Be the first: run equity_research_brief on CLX and publish the result to your public profile.
Get 15 years of data
Quarterly and annual financials back to 2011 on Pro (1993 on Institutional). Point-in-time accurate with zero survivorship bias.
View plansQuery via Python SDK
Pull data into DuckDB with 3 lines of Python. Works in Jupyter notebooks, scripts, and CI pipelines.
SDK docsConnect via MCP Server
Wire Claude, Cursor, or Codex directly to live SEC data with a single Bearer token. No scraping, no glue code.
MCP docs| $7.39B |
| $7.11B |
| $7.34B |
| Gross Profit | $3.21B | $3.05B | $2.91B | $2.54B | $3.20B |
|---|
| Operating Income | — | — | — | — | — |
|---|
| Net Income | $0.81B | $0.28B | $0.15B | $0.46B | $0.71B |
|---|
| EPS (Diluted) | $6.52 | $2.25 | $1.20 | $3.73 | $5.58 |
|---|
| Metric | FY25Jun '25 | FY24Jun '24 | FY23Jun '23 | FY22Jun '22 | FY21Jun '21 |
|---|---|---|---|---|---|
| Total Assets | $5.56B | $5.75B | $5.95B | $6.16B | $6.33B |
| Total Liabilities | $5.08B | $5.26B | $5.56B | $5.43B | $5.74B |
| Stockholders' Equity | $0.48B | $0.49B | $0.39B | $0.73B | $0.59B |
| Cash & Equivalents | $0.17B | $0.21B | $0.37B | $0.19B | $0.32B |
| Total Debt | — | — | — | — | — |
| Metric | FY25Jun '25 | FY24Jun '24 | FY23Jun '23 | FY22Jun '22 | FY21Jun '21 |
|---|---|---|---|---|---|
| Operating Cash Flow | $0.98B | $0.69B | $1.16B | $0.79B | $1.28B |
| Capital Expenditures | $0.22B | $0.21B | $0.23B | $0.25B | $0.33B |
| Free Cash Flow | $0.76B | $0.48B | $0.93B | $0.54B | $0.94B |
| Metric | FY25Jun '25 | FY24Jun '24 | FY23Jun '23 | FY22Jun '22 | FY21Jun '21 |
|---|---|---|---|---|---|
| Gross Margin | 45.2% | 43.0% | 39.4% | 35.8% | 43.6% |
| Operating Margin | 0.2% | 0.1% | 0.1% | 0.1% | 0.2% |
| Net Margin | 0.1% | 0.0% | 0.0% | 0.1% | 0.1% |
| Return on Equity | 166.3% | 63.6% | 26.7% | 69.9% | 94.7% |
| Return on Assets | 14.3% | 4.8% | 2.5% | 7.4% | 11.3% |
| Debt / Equity | 5.16× | 5.05× | 6.51× | 3.72× | 5.21× |
